Ledger. Australian venture funding, tracked

Medicine Development Leader, ENA Respiratory

Ruth Tal-Singer

Coverage

Stories naming Ruth Tal-Singer. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.

Funding announcement

ENA Respiratory Begins Part B Dosing

Melbourne biotech ENA Respiratory has begun dosing participants in the second part of its Phase IIa trial of INNA-051; its investor lineup, past government funding awards and BLUE KNIGHT alumni status are recapped.

Something wrong? Tell us